Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Anti-emetic Proemend IV Infusion 150 mg Approved: Ono
October 10, 2011
- Ilaris Approved as Japan’s 1st CAPS Treatment: Novartis Pharma
October 10, 2011
- Teribone Approved for Osteoporosis with High Fracture Risk: Asahi Kasei Pharma
October 10, 2011
- TachoSil Tissue Sealing Sheet Approved: CSL Behring
October 10, 2011
- Avastin Receives Add’l Indication for Breast Cancer: Chugai
October 10, 2011
- Onyx Submits NDA in US for Carfilzomib in MM: Ono
October 10, 2011
- Eisai, Abbott Japan File for Additional Indication for Humira
October 10, 2011
- CHMP Issues Positive Opinion on New ARB Edarbi: Takeda
October 10, 2011
- Takeda Aims at New Drug Development through Open Innovation
October 7, 2011
- Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
- Takeda US Unit Withdraw sNDA for Velcade
October 7, 2011
- Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
- Eli Lilly Receives Positive Opinion from CHMP for Alimta as Maintenance Therapy for NSCLC
October 7, 2011
- Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
- Ranbaxy Starts Selling Daiichi Sankyo Drugs in Italy
October 6, 2011
- Eli Lilly Japan Applies for Approval of Fast-Acting Zyprexa Intramuscular Inj.
October 6, 2011
- Nihon Chouzai Introduces Catalog Retailing at All Its Stores
October 6, 2011
- Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
- Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
- Rating Companies Downgrade Takeda following Acquisition of Nycomed
October 4, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…